OHSU study finds Oregon's regulated psilocybin program largely beneficial with few serious adverse reactions
Coveragetap to expand ▾Spectrum: Center Only🌍US: 1 · Other: 1
- The research was led by Dr. Todd Korthuis at Oregon Health & Science University.
- The study was published in the medical journal JAMA Network Open on August 19, 2026.
- Oregon's program is the first legalized and regulated psilocybin industry of its kind in the U.S.
- The study analyzed self-reported outcomes from clients who received psilocybin services at licensed providers in Oregon.
- Meaningful improvements reported after the psilocybin session were maintained at the three-month follow-up.
A team from Oregon Health & Science University led by Dr. Todd Korthuis reported that a real-world analysis of nearly 350 people who used psilocybin in state-licensed centers in Oregon produced largely favorable outcomes.
Published in JAMA Network Open on August 19, 2026, the study found most participants judged their sessions beneficial and that more than half described the session as among the most meaningful experiences of their lives (per NPR).
The researchers framed their work as the most rigorous look so far at a legalized, regulated psilocybin program operating outside conventional clinical trials.
NPR reports the study drew on people who accessed psilocybin through Oregon’s first-in-the-nation nonmedical, state-licensed program, and evaluated outcomes in that real-world service environment rather than under experimental conditions (per NPR).
The analysis also documented safety signals: NPR says the team recorded only a very small number of 'serious adverse reactions,' though the outlet does not list the exact events or counts in its summary (per NPR).
The study’s characterization of adverse reactions as limited is central to proponents’ arguments that regulated service models can expand access while managing risk; critics, however, typically press for larger controlled trials and clearer reporting of harms before broad expansion.
NPR’s report does not identify a funder for the research, and the article does not detail participant selection criteria, long-term follow-up intervals, or whether outcomes varied by participant demographics or clinical history (per NPR). Those omissions limit how confidently the results can be generalized beyond the cohort studied.
For practitioners and regulators, the distinction between 'real-world' program data and randomized clinical trials matters because implementation details—screening, preparation, and integration practices at licensed centers—drive both benefits and risks.
Advocates for legal, regulated access point to the study as evidence that Oregon’s program can deliver meaningful benefits to many users while keeping serious harms rare.
Skeptics note that observational, program-derived data can overstate benefit if participants self-select or if reporting focuses on those who complete follow-up assessments; NPR’s summary does not present subgroup analyses or retention figures that could address those concerns (per NPR).
The timing of the report—coming several years after Oregon established its regulated pathway—matters because regulators and other states are watching whether a licensed service model can produce robust outcomes outside clinical trials.
NPR’s coverage emphasizes promise but also signals the need for fuller transparency on adverse events, funding, and methodology before policymakers treat program data as definitive (per NPR).